HBV Cure Workshop 2018

Published on 09/11/2018

Pietro Scalfaro, Chief Medical Officer of ENYO Pharma, has participated to the 5th edition of the International HBV Cure Workshop 2018 on November 7 -8 in Toronto, Canada. The HBV Cure Workshop is a scientific platform that allows to accelerate the research in finding a cure of hepatitis B. During this event, researchers and clinical experts had the opportunity to discuss current challenges regarding the disease and to present research outcomes.

Read next in 'Latest news'

• La Phase 2
• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)